	US 11,918,585 B2
	Formulations of an AXL/MER inhibitor
William L. Rocco, Reading, PA (US); and Francis X. Muller, Chester Springs, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Dec. 28, 2021, as Appl. No. 17/563,282.
Application 17/563,282 is a continuation of application No. 16/456,547, filed on Jun. 28, 2019, granted, now 11,241,438.
Claims priority of provisional application 62/692,210, filed on Jun. 29, 2018.
Prior Publication US 2022/0273663 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/53 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 47/12 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/53 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2031 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/12 (2013.01); C07B 2200/13 (2013.01)]

55 Claims

1. A pharmaceutical formulation in solid oral dosage form comprising:

(a)N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof;

(b) an organic acid; and

wherein the pharmaceutical formulation comprises about 1 to about 100 mg of Compound I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, on a free base basis.